Active Ingredient History
Nicotine is a natural alkaloid obtained from the dried leaves and stems of the nightshade family of pants, such as Nicotiana tabacum and Nicotiana rustica, where it occurs in concentrations of 0.5-8%. Cigarette tobacco varies in its nicotine content, but common blends contain 15-25 mg per cigarette, with a current trend towards lower levels. Nicotine is highly addictive substance, it exhibits a stimulant effect when adsorbed at 2 mg. Administration of higher doses could be harmful. Action of nicotine is mediated by nicotinic cholinergic receptors. Nicotine binds to the interface between two subunits of the receptors, opens the channel and allows the entry of sodium or calcium. The principal mediator of nicotine dependence is α4β2 nicotine receptor. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Tobacco Use Disorder (approved 1984)
Acute Coronary Syndrome (Phase 3)
Adverse Childhood Experiences (Early Phase 1)
Aggression (Phase 1)
Aging (Early Phase 1)
Alcohol Drinking (Phase 4)
Alcohol-Induced Disorders (Phase 2/Phase 3)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Analgesics, Opioid (Phase 4)
Anxiety Disorders (Phase 1)
Autism Spectrum Disorder (Phase 1)
Behavior, Addictive (Phase 2)
Brain Diseases (Phase 2)
Breast Neoplasms (Phase 2)
Cannabis (Phase 2)
Carcinoma (Phase 4)
Carcinoma in Situ (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Cardiovascular Diseases (Phase 2)
Cigarette Smoking (Phase 4)
Cognition Disorders (Phase 1)
Cognitive Dysfunction (Phase 2)
Comorbidity (Phase 4)
Coronary Disease (Phase 4)
Coronavirus Infections (Phase 3)
Cost of Illness (Phase 3)
COVID-19 (Phase 3)
Critical Care (Phase 4)
Delirium (Phase 4)
Dental Pellicle (Phase 4)
Dentistry (Phase 4)
Depression (Phase 1/Phase 2)
Depressive Disorder (Phase 2)
Depressive Disorder, Major (Phase 4)
Diabetic Foot (Phase 1/Phase 2)
Down Syndrome (Phase 1/Phase 2)
Dronabinol (Phase 2)
Drug Interactions (Early Phase 1)
Drug Misuse (Phase 1/Phase 2)
Drugs, Investigational (Phase 4)
Dyslipidemias (Phase 3)
Electronic Nicotine Delivery Systems (Phase 4)
Endothelial Cells (Phase 1)
Esophageal Neoplasms (Phase 4)
General Surgery (Phase 4)
Habits (Phase 2/Phase 3)
Harm Reduction (Phase 3)
Head and Neck Neoplasms (Phase 4)
Healthy Aging (Phase 1)
Healthy Volunteers (Phase 1/Phase 2)
HIV (Phase 4)
HIV Infections (Phase 4)
Hypotension (Phase 1)
Irritable Mood (Phase 1)
Kidney Neoplasms (Phase 4)
Leukemia (Phase 4)
Liver Neoplasms (Phase 4)
Lung Neoplasms (Phase 4)
Marijuana Abuse (Phase 4)
Marijuana Smoking (Phase 2)
Memory Disorders (Phase 1)
Mental Disorders (Phase 4)
Metabolic Syndrome (Phase 3)
Methadone (Phase 4)
Motivation (Phase 4)
Neoplasms (Phase 2)
Neoplasms, Second Primary (Phase 2)
Neuralgia (Phase 2)
Nicotine (Phase 4)
Non-Smokers (Phase 1)
Obesity (Phase 2)
Opioid-Related Disorders (Phase 4)
Overweight (Phase 2)
Pain (Phase 4)
Pain, Postoperative (Phase 4)
Pancreatic Neoplasms (Phase 4)
Panic Disorder (Early Phase 1)
Parkinson Disease (Phase 4)
Pelvic Pain (Phase 4)
Peripheral Nerve Injuries (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Pharmacokinetics (Phase 1)
Postoperative Nausea and Vomiting (Phase 2)
Pregnancy (Phase 4)
Psychomotor Agitation (Phase 4)
Psychotic Disorders (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Respiration, Artificial (Phase 4)
Sarcoidosis (Phase 1/Phase 2)
Sarcoidosis, Pulmonary (Phase 4)
Sarcoma (Phase 2)
Schizophrenia (Phase 4)
Sleep Wake Disorders (Phase 4)
Small Cell Lung Carcinoma (Phase 1)
Smokers (Phase 4)
Smoking (Phase 4)
Smoking Cessation (Phase 4)
Stomach Neoplasms (Phase 4)
Stress Disorders, Post-Traumatic (Phase 2/Phase 3)
Substance Abuse, Oral (Phase 1)
Substance-Related Disorders (Phase 4)
Substance Withdrawal Syndrome (Phase 4)
Systemic Inflammatory Response Syndrome (Early Phase 1)
Tobacco (Phase 4)
Tobacco Smoking (Phase 4)
Tobacco Use (Phase 4)
Tobacco Use Cessation (Phase 4)
Tuberculosis (Phase 3)
Urinary Bladder Neoplasms (Phase 4)
Uterine Cervical Neoplasms (Phase 4)
Vaping (Phase 4)
Vascular Stiffness (Phase 1)
Weight Gain (Phase 2)
Weight Loss (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
